Agenus (AGEN) Cash from Financing Activities (2010 - 2026)
Agenus' (AGEN) quarterly Cash from Financing Activities came in at -$993000.0 in Q1 2026, down 127.63% year-on-year from $3.6 million in Q1 2025, and down 106.46% quarter-over-quarter from $15.4 million in Q4 2025.
Agenus (AGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Agenus' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$993000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 127.63% year-over-year to -$993000.0 in Q1 2026; TTM through Mar 2026 was $32.0 million, a 71.32% decrease from a year earlier, with the FY2025 full-year figure at $36.6 million, down 70.21% from the prior year.
- Cash from Financing Activities retreated to -$993000.0 in Q1 2026 per AGEN's latest filing, from $15.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $79.1 million in Q2 2024 and bottomed at -$993000.0 in Q1 2026.
- The 5-year median for Cash from Financing Activities is $16.0 million (2022), against an average of $22.0 million.
- Across the five-year window, Cash from Financing Activities jumped 250.73% in 2023 and slumped 127.63% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $23.8 million in 2022, then tumbled by 69.23% to $7.3 million in 2023, then soared by 233.15% to $24.4 million in 2024, then plunged by 36.91% to $15.4 million in 2025, then sank by 106.46% to -$993000.0 in 2026.
- Per Business Quant, the three latest AGEN Cash from Financing Activities figures stand at -$993000.0 (Q1 2026), $15.4 million (Q4 2025), and $6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Agenus | 184.05 Mn | 177.29 Mn | 33.74 Mn | -993,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -993,000.00 |
| Mar 31, 2026 | -993,000.00 |
| Dec 31, 2025 | 15.37 Mn |
| Dec 31, 2025 | 15.37 Mn |
| Sep 30, 2025 | 6.68 Mn |
| Sep 30, 2025 | 6.68 Mn |
| Jun 30, 2025 | 10.94 Mn |
| Jun 30, 2025 | 10.94 Mn |
| Mar 31, 2025 | 3.59 Mn |
| Mar 31, 2025 | 3.59 Mn |
| Dec 31, 2024 | 24.37 Mn |
| Dec 31, 2024 | 24.37 Mn |
| Sep 30, 2024 | 4.56 Mn |
| Sep 30, 2024 | 4.56 Mn |
| Jun 30, 2024 | 79.08 Mn |
| Jun 30, 2024 | 79.08 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Mar 31, 2024 | 14.83 Mn |
| Dec 31, 2023 | 7.32 Mn |
| Dec 31, 2023 | 7.32 Mn |